Relmada Therapeutics Inc (RLMD) - Revenue and Sales Volume
Reviewing the quarterly sales of Relmada Therapeutics (RLMD) on GURU.Markets, we observe that the value remains at 0.00. Relmada Therapeutics (RLMD) development is based on the automated synthesis of substances, although patient control remains with physicians. The massive potential of the antidepressant market promises colossal demand following approval. The asset's ultimate success relies on the safety of REL-1017 and the absence of side effects in the final phase of testing.
Comprehensive metric breakdowns and analytics for Relmada Therapeutics, Inc. (RLMD)
- current price and projected stock value:
- market capitalization indicators:
- company book value details:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Relmada Therapeutics|RLMD - Long-Term Debt to Capital|Current Liabilities to Capital Relmada Therapeutics Inc|RLMD - Company Debts|Debt to Net Assets Ratio Relmada Therapeutics, Inc.|RLMD - Company Long-Term Debts|Company Short-Term Debts Relmada Therapeutics|Critical Liquidity Ratio relmada.com
- earnings and valuation multiples indicators:
RLMD - Net Profit|Expected Net Profit Relmada Therapeutics|RLMD - Price to Earnings Ratio|Forward P/E Multiple relmada.com|RLMD - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Relmada Therapeutics, Inc.|RLMD - Operating profit EBITDA|Net earnings per share for the last four quarters Relmada Therapeutics|RLMD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months relmada.com|RLMD - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Relmada Therapeutics
- issuer revenue and sales details:
Comprehensive company analysis:Relmada Corp - RLMD
Investors are assessing fundamental risks through the lens of actual operational activity rather than static reports. For Relmada Therapeutics (RLMD), the results of Phase 3 antidepressant trials are critical, as they determine the future value of the business. This sales data series for the company captures daily revenue inflows, excluding GAAP accounting delays. The stability of this flow allows for the differentiation of speculative noise from sustainable commercial development.
Key competitors
Company Sales Volume BIIB (Biogen Idec)|Revenue and Sales Volume NBIX|Revenue and Sales Volume regencellbioscience.com (RGC)|Axsome Therapeutics, Inc. - Company Sales|Company Sales Revenue ACAD|XENE: Company Sales|Viking Therapeutics Corp - Company Total Sales|SUPN: Revenue and Sales Volume|catalystpharma.com - Company Sales Revenue|DNLI (Denali Therapeutics Inc.) - Revenue and Sales Volume|Company Total Revenue Harmony Biosciences Inc HRMY|Company Revenue Biohaven Pharmaceutical (BHVN)|AMLX (Amylyx Corp) - Company Sales Revenue|Revenue and Sales Volume TRVI (Trevi Therapeutics)|Revenue and Sales Volume praxismedicines.com PRAX|AVXL - Company Revenue|Company Annual Revenue CBLL|PRTA: Revenue and Sales Volume|Company Total Revenue Alector (ALEC)|Company Sales ANNX|Revenue and Sales Volume Omeros Corp.|Company Sales NGNE (Neurogene)|Company Total Sales ACIU|Revenue and Sales Volume VYGR (Voyager Pharma)|Company Gross Revenue Neumora Corp (NMRA)|Scilex Holding Company - Revenue and Sales Volume|tevogen.com (TVGN) - Company Sales|alphacognition.com (ACOG) - Company Revenue|CGTX - Company Gross Revenue|Company Revenue Inhibikase|SAVA: Company Sales Revenue|Company Revenue Assertio Holdings, Inc. (ASRT)|Company Revenue COYA (coyatherapeutics.com)|Company Revenue Vistagen VTGN|OVID - Company Sales|Acumen Pharma - Revenue and Sales Volume|CRVO (CervoMed Corporation) - Company Sales Volume|alteritytherapeutics.com (ATHE) - Company Revenue|Company Sales Volume CLNN|PEPG (PepGen Inc) - Revenue and Sales Volume|Company Total Revenue jupiterneurosciences.com JUNS|Company Sales ANVS (Annovis Bio Corp)|Revenue and Sales Volume gracetx.com (GRCE)|Company Revenue Firefly Neuroscience, Inc AIFF|Company Sales Revenue KLTO|NRSN - Company Revenue|Company Total Revenue Reviva Pharmaceuticals Holdings Inc.|metaviatx.com (MTVA) - Company Revenue|NeurAxis Inc - Company Sales Revenue|HSDT (Helius Medical Technologies, Inc.) - Revenue and Sales Volume|Company Total Revenue Passage Bio Corp PASG|Company Revenue Neuphoria Therapeutics Inc. (NEUP)|Company Revenue NERV (Minerva Neurosciences Inc)|Company Revenue Athira ATHA|ADXN - Company Sales|Alzamend - Revenue and Sales Volume|CYCN - Revenue and Sales Volume|PTIX: Revenue and Sales Volume|Company Sales Volume KTTA|CRGT (Cortigent Inc) - Revenue and Sales Volume|Revenue and Sales Volume Avenue Therapeutics Inc|Company Sales BCLI (Brainstorm Cell)|CARA (caratherapeutics.com) - Company Sales Revenue|Chromocell Therapeutics Corp. - Company Sales|Company Total Sales ELYM (Eliem Therapeutics, Inc.)|Intra-Cellular - Revenue and Sales Volume|Company Sales Revenue LBPH (Longboard)|MRNS: Revenue and Sales Volume|Company Total Revenue nkgenbiotech.com (NKGN)|Company Revenue NeuroBo Pharmaceuticals, Inc.|SAGE: Company Sales Revenue|Revenue and Sales Volume SNPX|Revenue and Sales Volume Trevena Inc (TRVN)|Company Revenue Vigil Neuroscience, Inc. VIGL|WENA (Anew Medical Inc.) - Company Annual Revenue|Cerevel Therapeutics, Inc. - Revenue and Sales Volume
